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Brain edema, the infiltration and accumulationof excess fluid cause an increase in braintissue volume, often leads to a rise in intracra-
nial pressure and is a key contributor to the morbidity
and mortality associated with traumatic brain injury (TBI).
The cellular and molecular mechanisms contributing to
the development /resolution of TBI-associated brain
edema are poorly understood. Recent data suggest that
aquaporin (AQP) water channels may have a central
role in keeping water homeostasis in the brain.
Aquaporin-4 (AQP4), the primary water channel, found
in the brain and expressed at high levels in brain
astrocytes, may play a crucial role in aggravation /reso-
lution of traumatic brain edema. In this review, we de-
scribed the structure and physiological function of
AQP4, its expression and regulation in the brain, and
discussed the newly discovered roles of AQP4 in trau-
matic brain edema.
Structure and physiological function of AQP4
The aquaporins (AQPs) are a family of small,
hydrophobic, integral membrane proteins that are ex-
pressed widely in animals and plants. AQP1 (CHIP28),
the first mammalian water channel to be functionally
characterized, was isolated from the membranes of red
blood cells as a 28-kDa protein and was shown to in-
crease membrane permeability in response to osmotic
gradients. The discovery of AQP1 triggered an immense
number of studies which advanced the current under-
standing of water permeation across biological
membranes. In 2003, Dr. Peter Agre was awarded the
Nobel Prize in Chemistry to signify the importance of
this discovery. To date, at least 13 AQP isoforms have
been identif ied from mammalian tissues (AQP0-
AQP12).1 While AQPs function primarily as water-trans-
porting channels, some of these proteins also exhibit
permeability to certain small solutes such as glycerol,
ammonia, hydrogen peroxide and some gases such
as carbon dioxide and nitric oxide.2 They are divided
into three subgroups based on the primary sequences:
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【Abstract】Brain edema leading to an expansion of
brain volume has a crucial impact on morbidity and mortal-
ity following traumatic brain injury as it increases intracra-
nial pressure, impairs cerebral perfusion and oxygenation,
and contributes to additional ischemic injuries. Classically,
two major types of traumatic brain edema exist: “vasogenic”
and “cytotoxic/cellular”. However, the cellular and molecu-
lar mechanisms contributing to the development/resolution
of traumatic brain edema are poorly understood and no ef-
fective drugs can be used now. Aquaporin-4 (AQP4) is a
water-channel protein expressed strongly in the brain, pre-
dominantly in astrocyte foot processes at the borders be-
tween the brain parenchyma and major fluid compartments,
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including cerebrospinal fluid and blood. This distribution
suggests that AQP4 controls water fluxes into and out of
the brain parenchyma. In cytotoxic edema, AQP4 deletion
slows the rate of water entry into brain, whereas in
vasogenic edema, AQP4 deletion reduces the rate of water
outflow from brain parenchyma. AQP4 has been proposed
as a novel drug target in brain edema. These findings sug-
gest that modulation of AQP4 expression or function may
be beneficial in traumatic brain edema.
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water selective AQPs (AQP0, 1, 2, 4, 5, 6, 8),
aquagl ycer opor i ns (AQP3,  7 ,  9 ,  10)  and
superaquaporins (AQP11, 12).3
The aquaporins share six transmembrane-spanning
domains and Asn-Pro-Ala (NPA) sequences. They have
similar molecular weights of approximate 30 kDa with
amino acid similarity from 20% to 50%. They are
tetramers, with each monomer having its own water
pore. The cDNA encoding AQP4 is obtained from brain
where the protein is abundant. This member of the
aquaporin family is not sensitive to mercurial inhibition
and lacks a cysteine preceding the NPA motif in loop E
which is known to confer mercurial sensitivity on AQP1.
AQP4 is otherwise constitutively active, similar to
AQP1. The primary sequence of aquaporin-4 (AQP4)
reveals two tandem sequence repeats, each formed from
three transmembrane domains with two highly con-
served loops (B and E) containing the signature motif,
NPA. The amino- and carboxy-termini are intracellular,
so the repeats are oriented at 180° to each other. The
two loops (B and E) fold into the membrane from the
opposite surfaces of the bilayer, overlapping midway
through the bilayer where they are surrounded by six
transmembrane helices and form a water channel pore.
Cryoelectron microscopy in combination with atomic
force microscopy and X-ray analysis confirm the so-
called “hourglass model” for aquaporin structure. It con-
sists of a wide extracellular and intracellular vestibule,
joined in the center by a narrow region of approximately
20 nm in length that shapes the filter responsible for
water selectivity. In the vestibules water exists in bulk
solution, while in the center of the channel water tran-
sits in single file. Actually it has been identified as a
two-stage filter in the central region of the pore: an outer
barrier termed as the aromatic/arginine constriction (ar/R),
and the central constriction or NPA region. Both stages
of the filter add to the remarkable efficiency and selec-
tivity of the AQPs.4 The filter selectivity appears to be
based on size exclusion, as the central constriction of
the filter is slightly wider than the water molecule (about
0.28 nm ) and represents a steric limit for bigger mol-
ecules through the channel. The ar/R constriction is
composed of a highly conserved arginine residue in the
195 position and a nearby histidine residue in the 180
position. This filter provides supplementary criteria for
solute selection, as the conserved residues have a
strong positive charge that repels protonated water. In
the NPA region, water-water interactions are distorted
so water molecules remain isolated from their solvation
shell in the bulk, a process essential for the filter
selectivity. As water molecules approximate to the
constriction, the oxygen atom rotates towards the as-
paragine residues from the NPA motifs (asparagines
76 and 192) and creates new hydrogen bonds between
the oxygen and the asparagine residues. The dipole
reorientation breaks the hydrogen bonds among water
molecules and avoids the passage of protonated water.
Based on the electron crystallographic structure of
AQPs, the hydrogen-bond isolation mechanism is pro-
posed to explain why AQPs are impermeable to pro-
tons despite their very fast water conduction. However,
the mechanism by which AQPs exclude protons re-
mains controversial. Recently the structure of AQP4
reveals eight water molecules in the channel. The ar-
rangement of the waters provides support for the hydro-
gen-bond isolation mechanism.5 The1.8-A crystal struc-
ture of AQP4 reveals the molecular basis for the water
selectivity of the channel. Unlike the case in the struc-
ture of AQP1, the asparagines of the 2 NAP motifs do
not bond to the same water molecule; instead, they
bond to 2 different water molecules in the center of the
channel.6
AQP4 forms a characteristic structure of square ar-
rays of intramembrane particles (also referred as as-
semblies or orthogonally arranged particles). AQP4
exists as two isoforms, differing at their N termini, be-
cause of translation initiation at the first methionine (M1,
323 amino acids) or the second methionine (M23, 301
amino acids). Endogenous AQP4 is a tetramer usually
containing M1 and M23 subunits. In the brain, M23 is
at least three-fold more abundant. Furman et al7 have
analyzed the difference between M1 and M23 in the
formation of square arrays. Chinese hamster ovary
(CHO) cells are transfected with M1, M23, or M1+M23
isoforms and perform freeze-fracture analysis. M23
homotetramers produce large square lattices with in-
ter-intramembrane particles cross-bridge, whereas M1
homotetramers produce dispersed 4- to 6-nm
intramembrane particles with few incipient square
arrays. When M1 and M23 are co-expressed to form
heterotetramers, square arrays are of intermediate
sizes, similar to square arrays in astrocyte endfeet.
Thus, factors affecting the selection of translation ini-
tiation sites may regulate the size of square arrays,
therefore, they may regulate local water permeability of
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the cells. Recent study showed that only the shorter
AQP4M23 isoform assembles into square arrays, while
the longer AQP4M1 isoform interferes with array
formation, presumably due to the additional 22 N-ter-
minal residues. Biochemical analysis and metabolic
labeling of transfected CHO cells revealed that the two
N-terminal cysteines at the position 13 and 17 of
AQP4M1 are palmitoylated, which is the reason for the
inability of AQP4M1 to form square arrays.8
AQP4 is recently found to have six isoforms, where
AQP4a (also known as M1), AQP4c (also known as
M23) and AQP4e are functional water transport
channels. The three isoforms lacking exon 2, AQP4b,
AQP4d and AQP4f, have an intracellular localization in
cell lines and do not transport water when expressed in
Xenopus oocytes. In contrast, the largest of the new
isoforms, AQP4e, which contains a novel N-terminal
domain, is localized at the plasma membrane in cell
lines and functions as a water transporter in Xenopus
oocytes. Isoforms AQP4a and AQP4e, which are not
able to form square arrays alone, can interact with
AQP4c and be incorporated into higher-order structures.9
Localization and regulation of AQP4 in the brain
AQP4 is the predominant subtype present in the
brain. AQP4 expression, studied using immunohis-
tochemistry and immunoelectron microscopy, is found
in glia only. AQP4 is expressed in astrocyte foot pro-
cesses surrounding capillaries, astrocyte processes
comprising the glial limiting membrane, in ependymal
cells and subependymal astrocytes. Although AQP4 is
also expressed in the supraoptic and suprachiasmatic
nuclei of the hypothalamus, AQP4-null mice do not have
hypothalamic disturbances. The pattern of AQP4 pro-
tein expression, predominantly at the borders between
the brain parenchyma and major fluid compartments,
suggests the involvement of AQP4 in water movement
into and out of the brain parenchyma. Kobayashi et al10
found that AQP4 mRNA and protein were present in the
microvessels prepared from rat cerebral cortex. In
addition, the microvessels were immunochemically
stained with anti-AQP4 antibody. Recent study at the
electron microscopy level has confirmed that AQP4 is
expressed in the microvascular endothelial cells.
However, AQP4 level of the abluminal membrane of the
brain endothelial cells is 1/5 of that of the endfeet of
astrocytes.
AQP4 is anchored by α-syntrophin (an adapter pro-
tein associated with dystrophin) and the interaction with
this molecule is essential for localization of AQP4. In
mice deleted α-syntrophin, most of the AQP4 disap-
peared from the endfoot membrane facing blood vessels,
whereas the AQP4 density of the membrane of the neu-
ropil side was increased.11 The distribution of AQP4 of
endothelial cells was not changed by α-syntrophin
deletion, indicating that localization of AQP4 in the
endfoot of astrocyte, but not that in the endothelial cell,
is regulated by its interaction with α-syntrophin. In the
intracellular region, AQP4 is anchored to several pro-
teins of the astrocytic cytoskeleton such as α-syntrophin
and dystrophin. Recent reports showed that the pres-
ence of AQP4 of the endfoot membrane is also depen-
dent on the presence of proteins in the basal lamina
such as agrin, dystroglycan and laminin, suggesting
an involvement in the ability of astrocytes to maintain
the integrity of the blood–brain barrier.12 A growing body
of evidence points to a role for dystroglycan and its
interaction with perivascular laminin in the targeting of
the dystrophin complex and the water-permeable
channel, AQP4, at astrocyte endfeet. However, the
mechanisms underlying such compartmentalization
remain poorly understood. The interdependence be-
tween laminin binding to dystroglycan and GM1-con-
taining lipid raft reorganization provides novel insight
into the dystrophin complex regulation of AQP4 polar-
ization in astrocytes.13 A recent study showed that in
the plasma membrane AQP4 is organized into several
distinct large multisubunit complexes (pools).14
Dystrophin-dependent AQP4 pool was immunolocalized
in perivascular astrocytes. Dystrophin-independent
pools were immunolocalized in the granular cell layer
of the cerebellum and in the subpial endfoot layer and
ependymal cells in the brain. These data provide a bet-
ter understanding on the association between AQP4
and the dystrophin-glycoprotein complex in the central
nervous system.
Accumulating evidence indicates that agrin, a
heparan sulphate proteoglycan of the extracellular
matrix, plays a role on the expression and distribution
of the water channel protein, AQP4. Noel et al15 found
that the orthogonally arranged particles (OAP) density
in agrin-null mice was dramatically decreased in com-
parison with wild-types. Neuronal and non-neuronal
agrin isoforms (agrin A4B8 and agrin A0B0, respectively)
were able to induce membrane-associated AQP4
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staining. Water transport capacity as well as the OAP
density was increased in astrocytes cultured with the
neuronal agrin isoform A4B8, but not with the endothe-
lial and meningeal isoform A0B0. RT-PCR demonstrated
that agrin A4B8 increased the level of the M23 splice
variant of AQP4 and decreased the level of the M1 splice
variant of AQP4. Moreover, depolymerization of F-actin
cytoskeleton performed by cytochalasin-D suggested
that F-actin cytoskeleton also plays a primary role in
AQP4 plasma membrane localization.16
It is well established that AQP4 water permeability
can be regulated by reversible protein phosphorylation.
Sequence analysis of the AQP4 molecule reveals sev-
eral potential phosphorylation sites for PKA, CaMKII,
PKC and CKII. Activation of PKC by phorbol esters
downregulates AQP4 water permeability both in Xeno-
pus oocyte expression system and in cultured kidney
epithelial cells.17 Furthermore, Yamamoto et al18 revealed
the PKC-mediated decrease of AQP4 mRNA and pro-
tein levels in rat astrocyte culture. This effect is medi-
ated via phosphorylation of Ser180, a consensus site
for PKC phosphorylation. The PKC-triggered
downregulation of AQP4 water permeability is likely due
to a gating effect. Activation of PKA is found to cause
an increase of water permeability of AQP4 expressed
in a renal cell line. The Ser111 residue of AQP4 is a
potential site for both calcium-dependent CaMKII phos-
phorylation and PKA phosphorylation. It is possible that
the AQP4-syntrophin interaction in astrocytes may pre-
vent PKC-dependent phosphorylation of Ser180 site,
and favor phosphorylation of Ser111 by CaMKII. Phorbol
myristate acetate (PMA) is a potent PKC activator,
purportedly involved in modulation of AQP4 activity.
Recent studies showed that PMA reduces ischemia-
induced AQP4 up-regulation and decreases ischemia-
induced brain edema (P<0.05).19
Several lines of evidence suggest that the activity of
AQP4 in brain cells is stimulated by AVP. AVP can
activate two types of receptors, V1 and V2. V1 recep-
tors are coupled to PLC, and activation of these recep-
tors leads to release of calcium from intracellular stores
and activation of several PKC isoforms. V2 receptors
are coupled to AC and trigger cAMP production and
activation of PKA. Many studies showed that the AVP-
induced changes in water transport were mediated by
V1 receptors. SR49059, the selective V1 receptor
antagonist, significantly reduced trauma-induced AQP4
up-regulation in the contused hemisphere. Moreover,
brain water content was also significantly reduced par-
alleling the AQP4 suppression. These data further sup-
port that vasopressin (AVP) and V1 receptors can con-
trol water flux through astrocytic plasma membranes
by regulating AQP4 expression.20
Both AQP4 and P2X7 receptor (P2X7R) are known
to be present in astrocytes. P2X7R activation in astro-
cytes is associated with down-regulation of AQP4 in
rat brain astrocytes in vitro and in vivo, and this is pre-
vented by P2X7 receptor blockade. Thus, an activation
of P2X7R in astrocytes in response to brain injury is
likely to play a role in the protective down-regulation of
AQP4, which might inhibit water influx to the cells and
attenuate the acute cytotoxic brain edema after acute
brain injury.21
AQP4 and traumatic brain edema
Traumatic brain edema    Classically, two major
types of traumatic brain edema exist: “vasogenic” due
to blood–brain barrier (BBB) disruption resulting in ex-
tracellular water accumulation and “cytotoxic/cellular”
due to sustained intracellular water collection. A third
type, “osmotic” brain edema, is caused by osmotic
imbalance between blood and tissue. Rarely after TBI
do we encounter a “hydrocephalic edema/interstitial”
brain edema related to an obstruction of cerebrospinal
fluid outflow.
For many years, vasogenic brain edema is accepted
as the prevalent edema type following TBI. The devel-
opment of mechanical TBI models (“weight drop,” “fluid
percussion injury,” and “controlled cortical impact injury”)
and the use of magnetic resonance imaging, however,
reveals that “cytotoxic” edema is of decisive pathophysi-
ological importance following TBI as it develops early
and persists while BBB integrity is gradually restored.
These findings suggest that cytotoxic and vasogenic
brain edemas are two entities which can be targeted
simultaneously or according to their temporal
prevalence.
Traumatic brain edema management includes se-
dation and avoidance of hypercapnia to prevent intrac-
ranial pressure elevation, administration of intravenous
hyperosmolar solutions such as mannitol and hyper-
tonic saline, corticosteroids for brain tumors, surgical
resection of the causative lesion, and in extreme cases,
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decompressive craniectomy. However, many of these
therapies to reduce brain swelling were introduced early
in the early/middle twentieth century and their efficacy
was limited. The paucity of effective drugs to be used in
brain edema reflects, in part, the incomplete understand-
ing of cellular mechanisms involved in brain edema for-
mation and resolution.
AQP4-null mice and cytotoxic edema    The first
evidence that AQP4 plays a major role in cytotoxic brain
edema came from studies with AQP4-null mice. Intrap-
eritoneal water injection causes profound hyponatre-
mia to 105 mmol/L within 5 minutes and subsequent
death from brain swelling and increased intracranial
pressure. Mortality after hyponatremia is markedly re-
duced in AQP4-null mice. Brains from AQP4 null mice
showed reduced osmotic water permeability as mea-
sured in isolated membrane vesicles, brain slices, and
intact brain.22 Also, water permeability was seven-fold
reduced in primary astrocyte cultures from AQP4-null
mice as measured by a calcein fluorescence quench-
ing method, indicating that AQP4 provides the predomi-
nant pathway for water movement in astrocytes. AQP4
deletion in mice conferred remarkable protection from
cytotoxic brain edema.
AQP4-null mice are also protected from other mod-
els of cytotoxic brain edema, including bacterial men-
ingitis and early focal cerebral ischemia.23 α-
syntrophin-null mice, which have reduced AQP4 expres-
sion in astrocyte foot precesses, are also protected
from cytotoxic brain edema produced by focal cerebral
ischemia. Together, these results provide direct func-
tional evidence for involvement of AQP4 in cytotoxic
brain edema, and suggest the potential use of AQP4-
selective inhibitors to reduce brain water accumulation
in cytotoxic edema.
AQP4-null mice and vasogenic brain edema
Because AQP4 permits bidirectional water transport,
AQP4 may facilitate the removal of excess brain water
in vasogenic (non-cellular) brain edema. This hypoth-
esis is supported by three models of vasogenic brain
edema in AQP4 null mice.24 Intracranial pressure (ICP)
and brain water content in AQP4-null mice are mark-
edly elevated after continuous slow intraparenchymal
fluid infusion of isosmolar artificial cerebrospinal fluid.
AQP4 null mice have more brain swelling compared
with wild-type mice after cortical freeze injury and brain
tumor implantation. Recently, in another clinically rel-
evant model of vasogenic brain edema and staphylo-
coccal brain abscess, significantly worse clinical out-
comes in AQP4 null mice were found, with greater ICP
elevation and brain water accumulation.25 Together, these
results support a novel role for AQP4 in the resolution
of vasogenic brain edema by a transcellular route.
In all brain edema types, excess fluid leaves the
brain parenchyma along three different routes: across
the blood–brain barrier into the bloodstream, across the
ependyma into the ventricles, and across the glia limit-
ing membrane into CSF in the subarachnoid space.
CSF eventually enters the arachnoid granulations and
is cleared into the superior sagittal venous sinus.
Vasogenic edema is generally believed to be cleared
primarily by bulk flow of fluid through the extracellular
space and glia limitans into the ventricles and subarach-
noid space. AQP4-rich astrocyte processes of the glia
limitans interna and glia limitans externa form a dense
mesh at the brain–CSF boundaries and ultrastructural
studies show that these long astrocytic processes are
separated by narrow intercellular clefts (<20 nm) and
are interconnected by gap junctions.26 AQP4 provides
a low resistance transcellular route and the enhanced
elimination of excess brain water through this transcellular
pathway would also accelerate the removal of associ-
ated solutes by creating a solute concentration gradi-
ent between brain parenchyma and CSF. It is possible
that in cytotoxic edema, the excess water initially re-
sides in the intracellular compartment but ultimately
moves to the extracellular space due to cell death and
regulatory volume decrease. Therefore, excess water
elimination routes in cytotoxic edema may be the same
as those in vasogenic edema.
AQP4 in traumatic brain edema    Further hints
of involvement of astrocytic AQP4 in traumatic cyto-
toxic brain edema has been demonstrated by Marmarou
and Amorini et al.27,28 Firstly, they demonstrated that
intravenous radio-active labeled Na+ (Na22) increased
after TBI which was obviously cleared intracellulary as
tissue microdialysis fluid did not show an increase in
Na+. Secondly, after the application of protein kinase C
activators causing AQP4 inactivation, both Na22 and
water content were reduced, providing support to the
notion that AQP4 dependent pathways for Na+ and water
exist in astrocytes contributing to cytotoxic brain
edema.
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Ke et al29 found AQP4 mRNA downregulation in the
contused cortex 24 hours after trauma, with no signifi-
cant change in the AQP4 expression level in the more
distant, ipsilateral basal ganglia and contralateral cortex.
A stepwise reduction of AQP4 on the traumatized hemi-
sphere over time was observed with a significant de-
crease at 48 hours after trauma. However, investiga-
tions on local AQP4 change after TBI did not add to a
consistent picture. Sun et al30showed an upregulation
of AQP4 occurs at the site of traumatic brain injury and
a downregulation of this molecule occurs adjacent to
the site of injury. To the contrary, Zhao et al31 show that
TBI decreased AQP4 level in the injury core and mod-
estly increased it in the penumbra region surrounding
the core.
Using a rat model of penetrating brain injury (PBI),
Neal et al32 found that AQP4 immunoreactivity was sub-
stantially increased in the peri-injury area and in the
injured tissue at both 24 and 72 hours after PBI. The
increase in AQP4 expression was paralleled by in-
creased GFAP expression. The two proteins were co-
expressed by peri-vascular astrocytes, whereas reac-
tive astroglia identified by their stellar morphology did
not express AQP4 at either time points after injury. The
apparent increase in AQP4 immunoreactivity was likely
due to de novo AQP4 protein synthesis, as most of the
increased AQP4 immunoreactivity was found in the
soluble (cytosolic) fraction. These results demonstrate
dynamic spatial and temporal changes in AQP4 ex-
pression that contribute to the molecular pathophysiol-
ogy of TBI. While AQP4 is capable to drive and resolve
brain edema, we still lack a full understanding of the
role of AQP4 under pathological conditions, such as
traumatic brain edema.
Apart from its role in brain edema, AQP4 was found
to play a major role in cell migration and neural excitability.33
AQP4 deficiency or knock-down slows astrocyte mi-
gration in response to a chemotactic stimulus in vitro,
and AQP4 deletion impairs glial scar progression fol-
lowing injury in vivo. AQP4-null mice also manifest re-
duced sound- and light-evoked potentials, and increased
threshold and prolonged duration of induced seizures.
Impaired K+ reuptake by astrocytes in AQP4 deficiency
may account for the neural signal transduction
phenotype.
AQP4, the new drug target for traumatic brain edema
Of the several aquaporin water channels expressed
in the central nervous system, AQP4 is an attractive
target for drug discovery. AQP4 has been implicated in
cytotoxic brain edema resulting from water intoxication,
brain ischemia or TBI. Inhibitors of AQP4 are of poten-
tial clinical utility, as they are predicted to modulate
brain edema, neuroexcitation and glial scarring.
Acetazolamide (AZA), a sulfonamide carbonic an-
hydrase (CA) inhibitor, has firstly been reported to in-
hibit AQP1-mediated water permeability in oocytes as
well as in mammalian cells. AZA has also been reported
to inhibit AQP4-mediated water permeability in oocytes.34
Yang et al35 reported that AZA did not inhibit water con-
duction by AQP1 or AQP4, and Sogaard and Zeuthen36
reported that AZA had no effect on water permeability
of oocytes expressing AQP1. Because AZA is an or-
ganic molecule and can be chemically modified, it is a
potential lead compound for the development of spe-
cific and selective inhibitors for AQPs. It is therefore
important to fully characterize the effect of AZA on AQP
mediated water conduction. Recently Tanimura et al37
showed that AZA reversibly inhibits water permeation
through AQP4, but not through AQP1. Methazolamide
(MZA), another sulfonamide CA inhibitor similar to AZA
in chemical structure, shows no significant effect on
water conduction by AQP4 or AQP1. These results thus
demonstrate that AZA acts as a reversible inhibitor for
AQP4-mediated water conduction and indicate that AZA
is specific, at least to some degree, for AQP4. AZA
may thus serve as a lead compound for the develop-
ment of AQP4-specific inhibitors for clinical applications.
AqB013, one of the synthesized bumetanide
derivatives, is the 4-aminopyridine 4-carboxamide
analog. Migliati et al38 showed that osmotic water flux
in AQP4-expressing Xenopus laevis oocytes was re-
duced by extracellular bumetanide (≥ 100 µmol/L).
AqB013 inhibited AQP1 and AQP4 (the half maximal
inhibitory concentration (IC50) was approximately 20
µmol/L and applied extracellularly). The efficacy of block
was enhanced by mutagenesis of intracellular AQP4
valine-189 to alanine (V189A), confirming the aquaporin
as the molecular target of block. IC50 was approximately
8 µmol/L. In silico docking of AqB013 supported an in-
tracellular candidate binding site in rat AQP4 and sug-
gested that the block involves occlusion of the AQP
water pore at the cytoplasmic side. Gating domains in
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aquaporins (AQPs) are molecular sites for drug actions.
Discovery of the arylsulfonamide AqB013 as an antago-
nist for AQP1 and AQP4 provides the first pharmaco-
logical agent with translational promise for the treat-
ment of diseases in which AQPs have been implicated.
Notwithstanding challenges in drug delivery to the
central nervous system and their multiplicity of actions,
AQP4 inhibitors have potential utility in reducing cyto-
toxic brain swelling, increasing seizure threshold and
reducing glial scar formation. Enhancers of AQP4 ex-
pression have potential utility in reducing vasogenic brain
swelling. AQP4 modulators may thus offer new thera-
peutic options for traumatic brain injury, stroke, tumour,
infection, hydrocephalus, epilepsy and spinal cord injury.
Conclusion
The discovery of the aquaporin family of membrane
water channels has provided important new insights into
the physiology and pathology of  brain water
homeostasis. A number of recent studies are described
in the review that demonstrate the important role of
AQP4 in brain water balance and cerebral edema. Phe-
notypic analyses of AQP4 deficient mice have allowed
us to explore the role of this membrane water channel
in the mechanisms of cytotoxic edema, vasogenic
edema. AQP4 plays a significant role in the develop-
ment of cytotoxic edema and the absorption of excess
brain water resulting from vasogenic edema, although
it has opposite roles. Aquaporins are targets for drug
discovery in basic research and medicine. Unfortunately
these efforts have not yet translated to the treatment of
human clinical diseases. These advances will require
the development of AQP inhibitors and activators to
establish the benefit modulating the function of these
water channels.
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